Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
The discovery and development of liraglutide and semaglutide
The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
J Lau, P Bloch, L Schäffer, I Pettersson… - Journal of medicinal …, 2015 - ACS Publications
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum
albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The …
albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The …
Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
Aim The aim of this trial was to investigate the mechanism of action for body weight loss with
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …
The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon
CB Christiansen, MBN Gabe… - American Journal …, 2018 - journals.physiology.org
The colonic epithelium harbors a large number of endocrine cells, but little is known about
the endocrine functions of the colon. However, the high density of glucagon like peptide-1 …
the endocrine functions of the colon. However, the high density of glucagon like peptide-1 …
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
RZ Alicic, EJ Cox, JJ Neumiller, KR Tuttle - Nature Reviews Nephrology, 2021 - nature.com
As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …
diabetic complications will reach an unprecedented magnitude. The emergence of new …
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …
care systems. Improving metabolic control to approach normal glycaemia (where practical) …
Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart …
AS Kelly, SE Barlow, G Rao, TH Inge, LL Hayman… - Circulation, 2013 - Am Heart Assoc
Severe obesity afflicts between 4% and 6% of all youth in the United States, and the
prevalence is increasing. Despite the serious immediate and long-term cardiovascular …
prevalence is increasing. Despite the serious immediate and long-term cardiovascular …
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
JJ Meier - Nature Reviews Endocrinology, 2012 - nature.com
In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …
[HTML][HTML] Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
Background Alcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts
for 5% of deaths annually, and there is an urgent need to develop new targets for …
for 5% of deaths annually, and there is an urgent need to develop new targets for …